Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by ABN Amro Investment Solutions

ABN Amro Investment Solutions cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.6% in the third quarter, Holdings Channel reports. The fund owned 23,860 shares of the medical equipment provider’s stock after selling 11,020 shares during the period. ABN Amro Investment Solutions’ holdings in Zimmer Biomet were worth $2,350,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ZBH. Vanguard Group Inc. increased its position in Zimmer Biomet by 0.9% during the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock worth $2,120,751,000 after purchasing an additional 198,370 shares during the last quarter. Dodge & Cox boosted its holdings in Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Zimmer Biomet by 8.7% in the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after buying an additional 458,903 shares during the period. Geode Capital Management LLC raised its position in shares of Zimmer Biomet by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after buying an additional 69,485 shares during the period. Finally, Primecap Management Co. CA raised its position in shares of Zimmer Biomet by 0.6% during the 2nd quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock valued at $429,675,000 after buying an additional 27,860 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wells Fargo & Company raised their target price on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 11th. Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $94.00 to $120.00 in a report on Monday, January 5th. BTIG Research reissued a “buy” rating and set a $112.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, February 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. Finally, Robert W. Baird reiterated a “neutral” rating and set a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Price Performance

Shares of ZBH opened at $96.32 on Monday. The company has a market cap of $19.09 billion, a P/E ratio of 27.21, a PEG ratio of 1.97 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The firm’s 50 day moving average price is $90.10 and its 200 day moving average price is $95.66.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.